Infectious Diseases & Immunology Division

Dr.Subhajit Biswas

Ph.D. (Cambridge Nehru Scholar), University of Cambridge, UK, 2004-2008

Post-doctoral Research Associate, School of Biological Sciences; School of Clinical Medicine, University of Cambridge, UK (2008-2012)

Lecturer (2012-2013); Senior Lecturer (2013-2014); School of Life Sciences, University of Lincoln, UK


Senior Scientist


Current Research Interest

Elucidate the molecular details of virus infection and pathogenesis, particularly virus replication; viral protein translation and trafficking; virus genome packaging and virus assembly with the aim of developing novel strategies of diagnosis and intervention (vaccines and antivirals).

Specific areas of interest:

a) Screening for and development of dengue virus antivirals.

b) Study the dynamics of resistance development to antivirals and characterisation of drug-resistant mutations.

c) Investigate the mechanisms of genesis of occult hepatitis B virus (HBV) infections (OBI), especially OBIs caused by altered production or secretion of HBV surface protein (S protein) or immune escape of the HBV surface antigen (HBsAg).

d) Elucidate the role of herpesvirus helicase and primase (conserved replication enzymes) in the biology of virus infections and exploitation of these enzymes as targets for antiviral development for human and veterinary medicine.

e) Decipher virus assembly and the regulation between virus protein translation and replication for nucleic acid packaging in progeny viruses (eg. rotaviruses).


Names of the group members including regular staff with designation and research fellows

Past Members

1. Dr Palashpriya Das (CSIR-SRA)

Research Fellows / RA

1. Ms Anisa Ghosh (CSIR-JRF)

2. Mr Subrata Roy (UGC-JRF)

3. Ms Sayantani Bhowmik (CSIR-JRF)

For Ph.D: CSIR/UGC/ICMR NET JRF awardees with background in microbiology/biochemistry and special interest in virology are welcome to apply via email (


List of important Publications

Research articles:

  1. Palashpriya Das, Suman Khowala, Subhajit Biswas. In vitro probiotic characterization of Lactobacillus casei isolated from marine samples. LWT - Food Science and Technology, Volume 73, November 2016, Pages 383-390. ISSN 0023-6438,
  2. Biswas S, Sukla S, Goldner T, Field HJ, Kropeit D, Paulsen D, Welbers A, Ruebsamen-Schaeff H, Zimmermann H & Birkmann A (2014). Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine HSV-1 infection model.  Antimicrobial Agents and Chemotherapy, 58, 3843-52. Impact Factor: 4.57
  3. Biswas S, Li W, Manktelow E, Lever J, Lukavsky PJ, Desselberger U & Lever AM (2014). Physicochemical analysis of rotavirus segment 11 supports a 'modified panhandle' structure and not the predicted alternative tRNA-like structure. Archives of Virology, 159, 235-48. Impact Factor: 2.03
  4. Biswas S, Candotti D¶  & Allain J-P (2013). Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection. Journal of Virology, 87, 7882-92. Impact Factor: 5.08 ¶ equal contribution.
  5. Candotti D, Lin CK, Belkhiri D, Sakuldamrongpanich T, Biswas S, Lin S, Teo D, Ayob Y & Allain J-P (2012). Occult Hepatitis B infection in asymptomatic blood donors from South East Asia: molecular characterization and potential mechanisms of occurrence. Gut-British Medical Journal, 61, 1744-53. Impact Factor: 10.73
  6. Sukla S, Biswas S¶, Birkmann A, Lischka P, Ruebsamen-Schaeff  H, Zimmermann H & Field HJ (2010). Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant. Antiviral Research, 87, 67-73. Impact Factor: 3.61
    ¶ Joint first author.
  7. Sukla S, Biswas S, Birkmann A, Lischka P, Zimmermann H & Field HJ (2010). Mis-match primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor. Journal of Antimicrobial Chemotherapy,65, 1347-52. Impact Factor: 5.34
  8. Biswas S, Núñez Miguel R, Sukla S & Field HJ (2009).  A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure. Journal of General Virology, 90, 1937-42. Impact Factor: 3.13
  9. Mohapatra JK, Sanyal A, Hemadri D, Tosh C, Biswas S, Knowles NJ, Rasool TJ, Bandyopadhyay SK & Pattnaik B (2008). Comparative genomics of serotype Asia 1 foot-and-mouth disease virus isolates from India sampled over the last two decades. Virus Research, 136, 16-29. Impact Factor: 2.75
  10. Biswas S, Tiley LS, Zimmermann H, Birkmann A & Field, HJ (2008). Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity. Antiviral Research,80, 81-5. Impact Factor: 3.93
  11. Biswas S, Kleymann G, Swift M, Tiley LS, Lyall J, Aguirre-Hernández J & Field HJ (2008). A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target. Journal of Antimicrobial Chemotherapy, 61, 1044-7. Impact Factor: 5.34
  12. Biswas S, Smith C & Field HJ (2007). Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in two of ten recent clinical isolates of HSV-1. Journal of Antimicrobial Chemotherapy, 60, 274-79. Impact Factor: 5.34
  13. Biswas S, Jennens L & Field HJ (2007). Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor, BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture. Archives of Virology, 152, 1489-500. Impact Factor: 2.03
    Citation: Faculty of 1000 Biology: evaluations for S Biswas et al Arch Virol 2007 Aug 152 (8): (Evaluated by Prof Donald Coen, Harvard Medical School, USA and selected as “New finding” in Microbiology).
  14. Biswas S, Swift M & Field HJ (2007). High frequency of spontaneous helicase primase inhibitor (BAY 57-1293) drug resistant variants in certain laboratory isolates of HSV-1. Antiviral Chemistry and Chemotherapy, 18, 13-23.  
  15. Biswas S, Jennens L & Field HJ (2007). The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type1. Antiviral Research, 75, 30-5. Impact Factor: 3.93
  16. Biswas S, Sanyal A, Hemadri D, Tosh C, Mohapatra JK, Kumar RM & Bandyopadhyay SK (2006). Sequence analysis of the non-structural 3A and 3C protein-coding regions of foot-and-mouth disease virus serotype Asia1 field isolates from an endemic country. Veterinary Microbiology,116, 187-93. Impact Factor: 3.13
  17. Biswas S, Sanyal A, Hemadri D, Tosh C, Mohapatra JK, Kumar RM & Bandyopadhyay SK (2005). Genetic comparison of large fragment of the 5'untranslated region among foot-and-mouth disease viruses with special reference to serotype Asia1. Archives of Virology, 150, 2217-39. Impact Factor: 2.03
  18. Sanyal A, Mohapatra JK, Kumar RM, Biswas S, Hemadri D, Tosh C, Sabarinath GP, Gupta SK, Mittal M, Giridharan P & Bandyopadhyay S (2004). Complete nucleotide sequence analysis of a vaccine strain (IND 491/97) and a field-isolate of foot-and-mouth disease virus serotype Asia 1 with an insertion in VP1 protein. Acta Virologica, 48, 159-66. Impact Factor: 0.76
  19. Biswas S, Sanyal A, Hemadri D, Tosh C, Gupta SK, Mittal M, Mohapatra JK, Sabarinath GP, Kumar RM & Bandyopadhyay SK (2004). Sequence analysis of VPg protein of Asia1 field isolates of foot-and-mouth disease virus in India. Journal of Animal and Veterinary Advances, 3, 522-26.


  1. Biswas S, Sukla S & Field HJ (2014). Helicase-primase inhibitors for HSV: looking back to the future of non-nucleoside inhibitors for treating herpesvirus infections. Future Medicinal Chemistry, 6, 45-55. Impact Factor: 3.31
  2. Field HJ & Biswas S (2011). Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus. Drug Resistance Update, 14, 45-51. Impact Factor: 12.58
  3. Biswas S & Field HJ (2008). Pointer: Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug-resistance mutations. Antiviral Chemistry and Chemotherapy,19, 1-6.
  4. Field HJ, Biswas S & Mohammad IT (2006).  Herpesvirus latency and therapy-From a veterinary perspective (Mini-review). Antiviral Research, 71, 127-33. Impact Factor: 3.93

Book chapter:

  1. Biswas S & Field HJ (2011). Helicase-primase inhibitors-a new approach to combat herpes simplex  virus and varicella zoster virus. Antiviral Drug Strategies (Wiley-VCH Verlag GmbH & Co. KGaA), Chapter 6, 129-46.

Link to publications in Pubmed


Go <<== Infectious Diseases & Immunology Division

Updated on 11th May, 2016

   © CSIR-IICB, Kolkata     Designed and Maintained by Computer Division ,CSIR - IICB